Susquehanna Fundamental Investments, LLC Supernus Pharmaceuticals, Inc. Transaction History

Susquehanna Fundamental Investments, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$27.11 - $35.17 $431,021 - $559,167	15,899 New	15,899 $542 Million
Q1 2023 May 16, 2023	SELL	$34.93 - $42.03 $293,272 - $352,883	-8,396 Reduced 15.1%	47,212 $1.71 Million
Q4 2022 Feb 14, 2023	SELL	$31.09 - $37.88 $131,510 - $160,232	-4,230 Reduced 7.07%	55,608 $1.98 Million
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $1.2 Million - $1.48 Million	41,852 Added 232.69%	59,838 $2.03 Million
Q1 2022 May 16, 2022	BUY	$28.51 - $32.9 $512,780 - $591,739	17,986 New	17,986 $581,000
Q3 2021 Nov 15, 2021	SELL	$23.54 - $31.39 $390,481 - $520,697	-16,588 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$26.72 - $33.19 $317,059 - $393,832	-11,866 Reduced 41.7%	16,588 $511,000
Q1 2021 May 17, 2021	BUY	$24.15 - $31.45 $372,127 - $484,613	15,409 Added 118.12%	28,454 $745,000
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $61,153 - $89,173	-3,455 Reduced 20.94%	13,045 $328,000
Q3 2020 Nov 16, 2020	BUY	$20.2 - $25.05 $20,200 - $25,050	1,000 Added 6.45%	16,500 $344,000
Q2 2020 Aug 14, 2020	BUY	$17.09 - $24.89 $264,895 - $385,795	15,500 New	15,500 $368,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.